After considering the feedback from consultation, the Appraisal Committee prepared a Final Appraisal Determination (FAD) on Denosumab for the prevention of osteoporotic fractures in postmenopausal women and submitted it to the Institute.

The FAD was sent to the formal consultees for this appraisal who had 15 working days to consider whether they wished to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.

Please note: the appeal period for this appraisal is now closed.